Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $23.13. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | KOLD | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $28.06 | $49.39 |
52-Week Low | $20.06 | $13.58 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
KOLD trades at $23.29, down 0.64% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The stock faces support at $23 and resistance at $24. Recent natural gas market volatility, driven by weather patterns and LNG demand fluctuations, creates trading opportunities for this bearish natural gas ETF.
As a tactical trading instrument, KOLD offers exposure to inverse natural gas price movements amid heightened energy market volatility. Key risks include weather-driven demand shifts and geopolitical factors affecting gas prices, while the bullish technical setup suggests potential near-term upside for this specialized energy sector play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
